247 Published Studies. 18,000 Patients Enrolled. One Focus.

Motility specializes in the full spectrum of gastrointestinal motility and functional disorders: achalasia, gastroparesis, chronic intestinal pseudo-obstruction, irritable bowel syndrome (IBS), functional dyspepsia, eosinophilic esophagitis, small intestinal bacterial overgrowth (SIBO), and inflammatory bowel disease (IBD) — including Crohn's disease and ulcerative colitis refractory to biologic therapy.[1]

Our diagnostic capability extends to microbiome-mediated dysmotility, bile acid malabsorption, and post-surgical gut reconstruction syndromes. If a community gastroenterologist has exhausted standard workup without a mechanistic answer, that case belongs here.

The center operates four high-resolution esophageal manometry suites (HRM with impedance), wireless pH-impedance monitoring, antroduodenal manometry, anorectal manometry with 3D mapping, and a dedicated SmartPill motility capsule program.[2]

Microbiome profiling is performed in-house via shotgun metagenomic sequencing (Illumina NovaSeq 6000) behind ISO 17025-certified containment. Results are co-interpreted with clinical phenotype within 10 business days.

Yes. Motility's IBD Refractory Program accepts referrals for patients who have failed two or more biologic classes (anti-TNF, anti-integrin, anti-IL-12/23) and remain in active disease by endoscopic criteria. Our protocol includes deep phenotyping — mucosal transcriptomics, mesenteric fat quantification by MR enterography, and fecal calprotectin kinetics — before recommending a mechanistic next step.[3]

Median time from referral acceptance to first appointment: 8 business days. Patients enrolled in parallel clinical trials receive no-cost investigational therapy where applicable.

Esophageal dysmotility unresponsive to proton pump inhibitor therapy is one of our highest-volume referral categories. We differentiate functional heartburn, hypersensitive esophagus, ineffective esophageal motility (IEM), and jackhammer esophagus using the Chicago Classification v4.0 protocol with adjunctive FLIP panometry.[4]

When structural and motility diagnoses are concurrent, our joint esophageal clinic — gastroenterology and thoracic surgery co-attending — produces a unified management plan in a single visit.

Submit referrals through the secure intake portal linked below — no fax required. Required fields: referring provider NPI, patient demographics, primary diagnosis code, reason for referral (one to three sentences), and any prior endoscopy or motility reports as PDF attachments.[5]

A triage coordinator contacts the referring practice within one business day to confirm receipt, classify urgency, and schedule. Urgent cases — active obstruction, severe malnutrition, or hospitalized patients — are triaged to our attending on-call line: (617) 555-0192.

At minimum: colonoscopy or upper endoscopy reports (if performed), relevant imaging (CT abdomen/pelvis, MR enterography), prior manometry or pH study tracings, current medication list, and a list of biologics or immunomodulators previously trialed with response documentation.

Incomplete referrals are not rejected — our coordinators will identify and request missing elements. However, complete records reduce time-to-first-appointment by an average of 3.4 days based on 2024 intake data.

Yes, and this is a formal commitment. Every patient evaluated at Motility generates a structured diagnostic summary — formatted as a clinical report, not a letter — transmitted to the referring provider within 5 business days of the final diagnostic procedure.[6]

Reports include: mechanistic diagnosis, supporting test data with tracings, proposed management algorithm with evidence tier (RCT vs. observational), and a clear co-management plan. Co-management is the default; transfer of care requires explicit mutual agreement.

Out-of-state referrals are accepted and represent 38% of our annual volume. International patients (primarily Canada, UK, and Gulf Cooperation Council countries) are accommodated with a dedicated international coordinator who manages visa documentation support, compressed diagnostic scheduling (all studies within 3 consecutive days), and telemedicine follow-up.

Insurance pre-authorization assistance is provided for all US-based commercial plans, Medicare, and Medicaid programs where in-network agreements exist. A current list of contracted payers is available through the referral portal.

As of February 2026, fourteen trials are open to enrollment across five therapeutic areas. Selected active studies:

Sponsor site qualification begins with our enrollment metrics package — available on request — which includes: historical enrollment velocity by therapeutic area, screen failure rates, protocol deviation frequency, and data quality audit results from the past three FDA inspections (zero Form 483 observations issued).[7]

Site initiation visits can be completed within 14 days of CTA execution. Our dedicated research coordinator team (12 FTE) maintains a 1:4 coordinator-to-study ratio, and our IRB operates on a 7-business-day expedited review track for qualifying protocols.

Yes. Referring physicians may indicate trial interest on the referral form, and our coordinators will pre-screen eligibility before the first appointment. Patients who consent to trial participation are enrolled in the same visit as their diagnostic evaluation wherever protocol allows.[8]

Patients not meeting eligibility for any open trial receive standard-of-care evaluation at no incremental cost. Trial participation is never a condition of access to Motility's diagnostic services.

Across 31 completed sponsored studies since 2018, Motility has achieved 94% of targeted enrollment within protocol timelines — ranking in the top decile of academic GI sites nationally by enrollment velocity (ClinTrials Benchmarking Consortium, 2024 Annual Report).[9]

Median time from first patient screened to last patient enrolled: 8.4 months (industry median: 14.2 months). This differential is driven by our referral network of 340 community gastroenterologists across six New England states feeding a pre-screened patient pool.